Similarly, if the landscape of AML therapy expands to embrace medicines targeting particular mutations, initiatives to add specific FLT3 or Isocitrate Dehydrogenase (IDH) inhibitors to CPX‐351 may provide further advances to existing AML treatment [17]. This evidence concerns the gene IDH3A and acute myeloid leukemia.